Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.
Nuvation Bio Inc (NUVB) is a clinical-stage biopharmaceutical company pioneering novel therapies for challenging cancers through innovative platforms like BD2-selective BET inhibitors and Drug-Drug Conjugate technology. This page serves as the definitive source for tracking the company’s progress in oncology research and corporate developments.
Investors and industry observers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships. All press releases and news articles are organized to provide clear insights into Nuvation Bio’s work targeting epigenetic regulators and advanced drug delivery systems.
Key content includes updates on lead candidate NUV-868, financial results, and scientific presentations. The page is regularly updated to reflect the most current information about the company’s efforts to develop precision oncology treatments.
Bookmark this page to stay informed about Nuvation Bio’s advancements in creating therapies for tumors resistant to conventional treatments. Check back frequently for verified updates directly from corporate communications and trusted industry sources.
Nuvation Bio Inc. (NYSE: NUVB) has initiated dosing in its Phase 1b study of NUV-868, targeting advanced solid tumors, in combination with olaparib or enzalutamide. The company also continues to enroll patients in a Phase 1 monotherapy study. Notably, Nuvation Bio plans to submit an IND for an undisclosed Drug-Drug Conjugate (DDC) candidate by the end of 2023. Financially, as of December 31, 2022, the company reported cash, cash equivalents, and marketable securities totaling $661 million. Q4 2022 net loss was $20.8 million, or $(0.10) per share, a decrease from $25.1 million, or $(0.12) per share, year-over-year, yet annual losses increased to $104.2 million.
Nuvation Bio (NYSE: NUVB) has commenced a Phase 1b study, dosing its first patient with NUV-868 in combination with olaparib for advanced solid tumors, including ovarian and pancreatic cancer. This study aims to assess the safety and optimal dosing of NUV-868, a BD2-selective BET inhibitor. A second regimen will evaluate NUV-868 in conjunction with enzalutamide for metastatic castration-resistant prostate cancer. The CEO, David Hung, highlighted this milestone as a step toward addressing significant unmet needs in oncology.
Nuvation Bio Inc. (NYSE: NUVB) announced that dosing is underway in a Phase 1 study of NUV-868 for advanced solid tumors, with a Phase 1b combination study expected to begin by the end of 2022. The company anticipates nominating its first clinical candidate from its Drug-Drug Conjugate platform by year-end. As of September 30, 2022, Nuvation Bio reported a strong financial position with $673.9 million in cash and equivalents. However, the company faced a net loss of $27.2 million for Q3 2022, compared to a net loss of $22 million for Q3 2021.
Nuvation Bio Inc. (NYSE: NUVB) is progressing its Phase 1 study of NUV-868 for advanced solid tumors, including ovarian and pancreatic cancers. As of June 30, 2022, the company reported a strong cash position of $703.8 million to fund operations through 2028. However, the company posted a net loss of $34.9 million, or $0.16 per share, an increase from a $19.3 million loss in Q2 2021. A recent restructuring resulted in a 35% workforce reduction to manage costs.
FAQ
What is the current stock price of Nuvation Bio (NUVB)?
What is the market cap of Nuvation Bio (NUVB)?
